Centre for Economic Evaluation, Trimbos-Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands.
Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, P.O. Box 616, 6200, Maastricht, The Netherlands.
Int Arch Occup Environ Health. 2020 Jan;93(1):123-132. doi: 10.1007/s00420-019-01471-y. Epub 2019 Aug 26.
The Stress-Prevention@Work implementation strategy has been demonstrated to be successful in reducing stress in employees. Now, we assess the economic return-on-investment to see if it would make for a favourable business case for employers.
Data were collected from 303 health-care workers assigned to either a waitlisted control condition (142 employees in 15 teams) or to Stress-Prevention@Work (161 employees in 15 teams). Main outcome was productivity losses measured using the Trimbos and iMTA Cost questionnaire in Psychiatry. Measurements were taken at baseline, 6, and 12 months post-baseline.
The per-employee costs of the strategy were €50. Net monetary benefits were the benefits (i.e., improved productivity) minus the costs (i.e., intervention costs) and were the main outcome of this investment appraisal. Per-employee net benefits amounted to €2981 on average, which was an almost 60-fold payout of the initial investment of €50. There was a 96.7% likelihood for the modest investment of €50 to be offset by cost savings within 1 year. Moreover, a net benefit of at least €1000 still has a likelihood of 88.2%.
In general, there was a high likelihood that Stress-Prevention@Work offers an appealing business case from the perspective of employers, but the employer should factor in the additional per-employee costs of the stress-reducing interventions. Still, if these additional costs were as high as €2981, then costs and benefits would break even. This study was registered in the Netherlands National Trial Register, trial code: NTR5527.
“工作压力预防”实施策略已被证明可成功减轻员工压力。现在，我们评估投资的经济回报，以确定其是否对雇主具有有利的商业案例。
从分配到候补对照组（15 个团队中的 142 名员工）或“工作压力预防”组（15 个团队中的 161 名员工）的 303 名医护人员中收集数据。主要结果是使用 Trimbos 和 iMTA 精神病学成本问卷测量的生产力损失。测量在基线、6 个月和 12 个月后进行。
该策略每名员工的成本为 50 欧元。净货币收益是收益（即提高生产力）减去成本（即干预成本），是这项投资评估的主要结果。平均而言，每名员工的净收益为 2981 欧元，这是初始投资 50 欧元的近 60 倍回报。在 1 年内，适度投资 50 欧元几乎有 96.7%的可能性抵消成本节省。此外，仍有 88.2%的可能性获得至少 1000 欧元的净收益。
一般来说，从雇主的角度来看，“工作压力预防”极有可能提供有吸引力的商业案例，但雇主应考虑减轻压力干预措施的额外每名员工成本。尽管如此，如果这些额外成本高达 2981 欧元，则成本和收益将收支平衡。本研究在荷兰国家试验登记处注册，试验代码：NTR5527。
